

Urine di-(2-ethylhexyl) phthalate metabolites are independently related to body fluid status in adults: Results from a U.S. nationally representative survey

Wei-Jie Wang

Taoyuan General Hospital

Chia-Sung Wang

En Chu Kong Hospital

Chi-Kang Wang

Yuanpei University of Medical Technology

An-Ming Yang

En Chu Kong Hospital

Chien-Yu Lin (✉ lin7010@mail2000.com.tw)

En Chu Kong Hospital

Research Article

Keywords: Di-(2-ethylhexyl) phthalate, Bioelectrical impedance analysis, Extracellular fluid, National Health and Nutrition Examination Survey, Obesity

Posted Date: March 1st, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-827766/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Purpose

Di-(2-ethylhexyl) phthalate (DEHP) has been utilized in many daily products for decades. Previous studies have reported that DEHP exposure could induce renin-angiotensin-aldosterone system activation and increase epithelial sodium channel (ENaC) activity, which contributes to extracellular fluid (ECF) volume expansion. However, there is also no previous study to evaluate the association between DEHP exposure and body fluid status.

Methods

We selected 1,678 subjects (aged ≥ 18 years) from a National Health and Nutrition Examination Survey (NHANES) in 2003–2004 to determine the relationship among urine DEHP metabolites and body composition (body measures, bioelectrical impedance analysis (BIA)).

Results

After weighing the sampling strategy in multiple linear regression analysis, we report that higher levels of DEHP metabolites are correlated with increases in body measures (body weight, body mass index (BMI), waist circumference), BIA parameters (estimated fat mass, percent body fat, ECF, and ECF/intracellular fluid (ICF) ratio) in multiple linear regression analysis. The relationship between DEHP metabolites and the ECF/ICF ratio was more evident in subjects with younger age (20–39 years old), women, non-Hispanic white ethnicity, and subjects who were not active smokers.

Conclusion

In addition to being positively correlated with body measures and body fat, we found that urine DEHP metabolites were positively correlated with ECF and the ECF/ICF ratio in the US general adult population. Further research is needed to clarify the causal relationship.

Introduction

Phthalates, known as endocrine-disrupting chemicals (EDCs), are the most common chemicals widely used in many products to increase flexibility^{1,2}. People are widely exposed to phthalates because their metabolites are commonly detected in urine samples around the world³. Although the half-life of phthalates is only approximately 12 hours⁴, due to continuous exposure, their effects are similar to those of persistent and bioaccumulating compounds⁵. Among the compound esters of phthalates, di-(2-ethylhexyl) phthalate (DEHP) has been the main plasticizer used for decades⁶. Recently, several epidemiological studies have linked DEHP exposure to several cardiovascular disease risk factors, such as diabetes mellitus⁷ and higher systolic blood pressure⁸.

In healthy adults, extracellular fluid (ECF) content comprises ~ 33 – 40% of total body water⁹ and is regulated by the activity of the renin-angiotensin-aldosterone system (RAAS), autonomic nervous system, hormones, and natriuretic peptides¹⁰. The increased ECF might cause stress in the cardiovascular system, which eventually contributes to hypertension¹¹ and has been reported as an independent predictor of cardiovascular morbidity in patients with chronic renal failure¹². The ECF/intracellular fluid (ICF) volume ratio also shows a significant association with chronic disease^{13–16}. Recently, many environmental chemicals were reported to influence blood pressure and ECF¹⁷. The mechanism was related to the activation of RAAS by inhibiting 11β hydroxysteroid dehydrogenase and type 2 (11β -HSD-2) enzyme activity¹⁷. The activation of RAAS contributes to sodium retention and ECF expansion¹⁸. Previous animal and human studies have reported that DEHP exposure is associated with the activation of the RAAS through inhibiting 11β -HSD-2^{19,20}. Moreover, DEHP exposure might increase the risk of obesity²¹, while adipocytes are an important source of extra-adrenal aldosterone²². In addition, DEHP has been reported to increase epithelial sodium channel (ENaC) activity in renal cortical collecting duct cells²⁰ and have affinity with the receptors of peroxisome proliferator-activated receptor (PPAR) γ ²³, which can expand the ECF volume in turn^{24,25}. However, no previous epidemiological study has investigated the relationship between DEHP exposure and fluid status.

Bioimpedance analysis (BIA) is a tool for measuring the electrical impedance of human tissues and can be used to assess the proportion of lean mass, fat, and body fluids²⁶. Unlike fluid volume, the association between DEHP exposure and other body measures has been extensively studied. When using body mass index (BMI), weight, and waist circumference as parameters, some results showed that higher levels of urine DEHP metabolites showed a positive correlation^{27–29}, while others showed no correlation³⁰ or an inverse association³¹. The relationship between DEHP exposure and body fat percentage has been most investigated in children, and the results are inconsistent^{32–35}. In adults, however, there are only a few studies studying the association between DEHP exposure and lean mass/body fat percentage, and the results are also inconsistent.^{36,37}

Since the relationship between DEHP exposure and fluid status is unknown, we included subjects enrolled by the National Health and Nutrition Examination Survey (NHANES). In the NHANES database, BIA measurements were available between 1999 and 2004. However, detailed urine DEHP metabolites were only available in NHANES 2003–2004. We hypothesized that urine DEHP metabolites may have a positive correlation with body measures, lean mass, fat mass, and body fluids in the NHANES 2003–2004 database, which has detailed information on urine DEHP metabolites, body measures, BIA, and various covariates.

Materials And Methods

Study design and population:

The data for this study were obtained from NHANES 2003–2004. NHANES is a study of a representative sample of the U.S. population that collects information about family health and nutrition. The survey data is released every two years. Detailed contents of the NHANES 2003–2004 are available at the NHANES website ³⁸. Our analysis included 1,678 participants over the age of 18 without missing data on basic demographics and BMI and those who had undergone urine DEHP metabolite testing. All methods were carried out in accordance with relevant guidelines and regulations.

Urine DEHP metabolites:

In NHANES 2003–2004, urine DEHP metabolites, including mono (2-ethylhexyl) phthalate (MEHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono(2-ethyl-5-carboxypentyl) phthalate (MECPP), were tested using high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. For concentrations below detection limits, a value was assigned by NHANES. We used this value in our analyses. The detailed method is available in the supplemental section.

Body Measures:

The body measurement assessments performed on survey participants varied according to the participants' ages. Weight, BMI, triceps, and subscapular skinfold were measured in NHANES 2003–2004. The detailed method is available in the supplemental section.

Bioelectrical Impedance Analysis (BIA):

In NHANES 2003–2004, this examination was conducted in an eligible survey with participants 8–49 years of age. The BIA data were collected with a HYDRA ECF/ICF Bio-Impedance Spectrum Analyzer (Model 4200, Xitron Technologies, Inc., San Diego, California, USA). Detailed information is available in the supplemental section.

Covariates:

We considered age, gender, race/ethnicity, education level, household income, smoking status, caffeine intake, total energy intake, total protein intake, total sugar intake, total carbohydrate intake, total saturated fatty acid intake, and metabolic equivalent intensity level for activity to be potential confounders in this study. Detailed information is available in the supplemental section.

Statistics

DEHP metabolite concentrations were corrected for urine creatinine and expressed as the geometric mean (geometric standard error) in different subpopulations. These variables were tested by Student's 2-tailed t test and one-way analysis of variance. Because DEHP is metabolized primarily into MEHP, MEOHP, MEHHP, and MECPP, we divided the level of each metabolite by its molar mass and then added the concentrations of each metabolite to calculate Σ DEHP ³⁹. Due to the obvious deviation from the normal distribution, the DEHP metabolites were transformed by natural logarithm. We constructed an extended model approach with body measures/bioelectrical impedance analysis as the dependent variable and individual In-DEHP metabolites as a predictor. Model 1 adjusted for age, gender, race and ethnicity, education level, household income, smoking status, and metabolic equivalent intensity level for activity. Model 2 adjusted for Model 1 plus caffeine intake, total energy intake, total protein intake, total sugar intake, total carbohydrate intake, and total saturated fatty acid intake.

We used sample weights for analysis to understand the impact of weights. The calculation of sampling weight follows the analysis guidelines of the National Center for Health Statistics and appropriately considers the complex survey design adopted in NHANES 2003–2004 ⁴⁰. All analyses were calculated by SPSS Version 20 (SPSS Inc. Chicago, Illinois, U.S.A.). $P < 0.05$ was considered significant.

Results

MEHP, MEOHP, MEHHP, and MECPP were detectable in 69.9%, 99.1%, 99.7%, and 100% of study subjects, respectively. Table 1 shows the basic demographics of the study subjects. The study participants were composed of 798 men and 880 women. Subjects aged between 18–39 years old, women, and those with higher education levels were associated with higher DEHP metabolite concentrations and Σ DEHP. In addition to MEHP, subjects with higher income were associated with higher levels of other DEHP metabolites and Σ DEHP, while these metabolite levels were different between races. Participants with a BMI between 25–30 had a lower concentration of DEHP metabolites and Σ DEHP, while active smokers had a lower concentration of MEOHP, MECPP, and Σ DEHP. Those who had a body fat percentage $\geq 35\%$ had higher levels of MEOHP, MECPP, and Σ DEHP.

Table 1
Basic demographics of the sample subjects, including geometric means (geometric S.E.) of DEHP metabolites concentrations

	Unweighted no. (%)	MEHP (µg/g)	MEOHP (µg/g)	MEHHP (µg/g)	MECPP (µg/g)	Σ DEHP (µmol/g)
Overall	1678 (100)	2.13 (1.03)	12.18 (1.03)	18.23 (1.03)	29.44 (1.03)	0.21(1.03)
Age, y						
18–39	718 (42.8)	2.64 (1.05) [‡]	13.63 (1.05) [‡]	20.15 (1.05) [†]	30.88 (1.04) [†]	0.23 (1.04) [†]
40–59	449 (26.8)	1.90 (1.06) [‡]	10.67 (1.05) [‡]	16.33 (1.05) [†]	25.89 (1.05) [†]	0.19 (1.05) [†]
≥60	511 (30.4)	1.72 (1.05) [‡]	11.70 (1.04) [‡]	17.46 (1.04) [†]	30.81 (1.04) [†]	0.21 (1.04) [†]
Gender						
Men	798 (47.6)	1.85 (1.05) [‡]	10.74 (1.04) [‡]	16.52 (1.04) [‡]	26.08 (1.04) [‡]	0.19 (1.04) [‡]
Women	880 (52.4)	2.41 (1.04) [‡]	13.66 (1.04) [‡]	19.94 (1.04) [‡]	32.86 (1.03) [‡]	0.24 (1.03) [‡]
Race						
Mexican American	365 (21.8)	1.96 (1.06)	10.36 (1.06)*	15.18 (1.06)*	26.30 (1.05)*	0.19 (1.05)*
Other Hispanic	48 (2.9)	2.63 (1.17)	12.92 (1.17)*	19.59 (1.18)*	32.47 (1.14)*	0.24 (1.15)*
Non-Hispanic White	842 (50.2)	2.09 (1.04)	12.91 (1.04)*	19.19 (1.04)*	32.00 (1.04)*	0.23 (1.04)*
Non-Hispanic Black	345 (20.6)	2.37 (1.07)	12.72 (1.06)*	19.64 (1.06)*	26.91 (1.06)*	0.21 (1.06)*
Others	78 (4.5)	2.02 (1.14)	11.09 (1.13)*	17.09 (1.13)*	28.41 (1.12)*	0.20 (1.12)*
Education levels						
≤High school	927 (55.3)	1.94 (1.04) [‡]	10.85 (1.03) [‡]	16.04 (1.04) [‡]	26.54 (1.03) [‡]	0.19 (1.03) [‡]
>High school	750 (44.7)	2.37 (1.05) [‡]	14.06 (1.04) [‡]	21.35 (1.04) [‡]	33.47 (1.04) [‡]	0.25 (1.04) [‡]
Annual household income						
<\$25000	556 (35.6)	2.02 (1.05)	10.98 (1.05) [‡]	16.50 (1.05) [‡]	27.52 (1.04) [†]	0.20 (1.04) [‡]
\$25000–55000	503 (32.2)	2.00 (1.05)	11.54 (1.05) [‡]	17.24 (1.05) [‡]	27.89 (1.05) [†]	0.20 (1.05) [‡]
>\$55000	501 (32.2)	2.31 (1.06)	14.07 (1.05) [‡]	21.06 (1.05) [‡]	33.01 (1.05) [†]	0.24 (1.05) [‡]
BMI, kg/m ²						
<25	577 (34.4)	2.31 (1.05)*	11.92 (1.05) [‡]	17.77 (1.05) [‡]	28.71 (1.05)*	0.21 (1.05) [‡]
25–30	562 (33.5)	1.90 (1.05)*	10.93 (1.05) [‡]	16.31 (1.05) [‡]	27.29 (1.04)*	0.20 (1.04) [‡]
≥ 30	539 (32.1)	2.19 (1.05)*	13.97 (1.05) [‡]	21.06 (1.05) [‡]	32.73 (1.04)*	0.24 (1.04) [‡]
Body fat percentage (%)						
<25	227(31.4)	2.22 (1.09)	10.70 (1.08)*	16.81 (1.09)	25.82 (1.08)*	0.19 (1.08)*
25–35	230(31.9)	2.00 (1.09)	11.33 (1.08)*	17.11 (1.08)	25.87 (1.07)*	0.20 (1.07)*
≥ 35	265(36.7)	2.53 (1.08)	14.19 (1.07)*	20.83 (1.08)	32.21 (1.07)*	0.24 (1.07)*
Smoking						
Nonexposed	353 (21.0)	2.16 (1.07)	12.10 (1.06)*	18.26 (1.06)	31.27 (1.05) [‡]	0.22 (1.06)*
Expose to ETS	849 (50.6)	2.15 (1.04)	12.99 (1.04)*	19.04 (1.04)	31.15 (1.04) [‡]	0.23 (1.04)*
Active smokers	476 (28.4)	2.07 (1.06)	10.93 (1.05)*	18.23 (1.05)	25.46 (1.05) [‡]	0.19 (1.05)*
Alcohol consumption (drinks/year)						

*, p < 0.05; †, p < 0.01; ‡, p < 0.005 (tested by Student's 2-tailed t test or by one-way analysis of variance)

Abbreviations: DEHP, di-(2-ethylhexyl) phthalate; ETS, Environmental tobacco smoke; MEHP, mono(2-ethylhexyl) phthalate; MEHHP, mono(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono(2-ethyl-5-oxohexyl) phthalate; MECPP, mono(2-ethyl-5-carboxypentyl) phthalate.

Σ DEHP was the sum of (MEHP/278) + (MEHHP/294) + (MEOHP/292) + (MECPP/308) and corrected for urine creatinine

	Unweighted no. (%)	MEHP (µg/g)	MEOHP (µg/g)	MEHHP (µg/g)	MECPP (µg/g)	Σ DEHP (µmol/g)
<12	412 (29.5)	2.01 (1.06)	11.86 (1.05)	17.38 (1.05)	2.52 (1.05)	0.21 (1.05)
≥ 12	983 (70.5)	2.05 (1.04)	11.89 (1.04)	17.97 (1.04)	2.32 (1.03)	0.21 (1.03)
*, p < 0.05; †, p < 0.01; ‡, p < 0.005 (tested by Student's 2-tailed t test or by one-way analysis of variance)						
Abbreviations: DEHP, di-(2-ethylhexyl) phthalate; ETS, Environmental tobacco smoke; MEHP, mono(2-ethylhexyl) phthalate; MEHHP, mono(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono(2-ethyl-5-oxohexyl) phthalate; MECPP, mono(2-ethyl-5-carboxypentyl) phthalate.						
Σ DEHP was the sum of (MEHP/278) + (MEHHP/294) + (MEOHP/292) + (MECPP/308) and corrected for urine creatinine						

The means and S.E. of body fluid status between basic demographic of the sample subjects are shown in Table 2. Men, higher household income, higher BMI, lower body fat percentage, active smoking, and higher alcohol consumption were associated with higher ECF and ICF volumes. A higher ECF volume was also found in subjects who were non-Hispanic white. Subjects aged between 40–59 years old, women, higher education level, lower BMI, higher body fat percentage, and lower alcohol consumption were associated with a higher ECF/ICF ratio, while a lower ECF/ICF ratio was found in other Hispanics.

Table 2
Basic demographics of the sample subjects, including means (S.E.) of body fluid status

	Unweighted no. (%)	ECF (L)	ICF (L)	ECF/ICF ratio
Overall	726 (100)	16.92 (0.13)	23.35 (0.24)	0.74 (0.00)
Age, y				
18–39	524 (42.8)	16.80 (0.16)	23.42 (0.29)	0.74 (0.00) ‡
40–50	202 (26.8)	17.24 (0.24)	23.16 (0.42)	0.76 (0.01) ‡
Gender				
Men	377 (47.6)	19.00 (0.15) ‡	27.61 (0.28) ‡	0.70 (0.00) ‡
Women	349 (52.4)	14.67 (0.15) ‡	18.74 (0.22) ‡	0.79 (0.00) ‡
Race				
Mexican American	172 (21.8)	15.95 (0.23) ‡	22.32 (0.43)	0.73 (0.01)*
Other Hispanic	27 (2.9)	15.99 (0.64) ‡	22.92 (1.28)	0.72 (0.02)*
Non-Hispanic White	319 (50.2)	17.45 (0.21) ‡	23.78 (0.38)	0.75 (0.01)*
Non-Hispanic Black	172 (20.6)	17.13 (0.27) ‡	23.78 (0.49)	0.74 (0.01)*
Others	36 (4.5)	16.59 (0.65) ‡	22.70 (1.22)	0.75 (0.01)*
Education levels				
≤High school	376 (55.3)	16.88 (0.18)	23.58 (0.33)	0.73 (0.00) ‡
>High school	350 (44.7)	16.97 (0.20)	23.10 (0.36)	0.75 (0.00) ‡
Annual household income				
<\$25000	203 (35.6)	16.40 (0.23) ‡	22.50 (0.41)*	0.74 (0.01)
\$25000–55000	227 (32.2)	16.79 (0.24) ‡	23.32 (0.44)*	0.74 (0.01)
>\$55000	248 (32.2)	17.62 (0.24) ‡	24.25 (0.45)*	0.75 (0.00)
BMI, kg/m ²				
<25	301 (34.4)	15.04 (0.18) ‡	20.04 (0.31) ‡	0.77 (0.01) ‡
25–30	218 (33.5)	17.22 (0.20) ‡	24.35 (0.38) ‡	0.72 (0.01) ‡
≥ 30	207 (32.1)	19.35 (0.23) ‡	27.10 (0.46) ‡	0.73 (0.01) ‡
Body fat percentage (%)				
<25	229 (31.4)	18.52 (0.21) ‡	27.79 (0.38) ‡	0.67 (0.00) ‡
25–35	230 (31.9)	16.94 (0.26) ‡	23.24 (0.42) ‡	0.74 (0.00) ‡
≥ 35	267 (36.7)	15.54 (0.19) ‡	19.62 (0.29) ‡	0.80 (0.01) ‡
Smoking				
Nonexposed	109 (21.0)	15.91 (0.35) ‡	21.45 (0.60) ‡	0.76 (0.01)
Expose to ETS	356 (50.6)	16.74 (0.19) ‡	23.23 (0.35) ‡	0.74 (0.00)
Active smokers	257 (28.4)	17.63 (0.21) ‡	24.39 (0.39) ‡	0.74 (0.01)
Alcohol consumption (drinks/year)				
<12	124 (29.5)	16.34 (0.36) ‡	21.87(0.62) ‡	0.77 (0.01) ‡

*, p < 0.05; †, p < 0.01; ‡, p < 0.005 (tested by Student's 2-tailed t test or by one-way analysis of variance)

Abbreviations: ETS. Environmental tobacco smoke;

	Unweighted no. (%)	ECF (L)	ICF (L)	ECF/ICF ratio
≥ 12	429 (70.5)	17.43 (0.17) [‡]	24.23 (0.31) [‡]	0.74 (0.00) [‡]
*, p < 0.05; †, p < 0.01; ‡, p < 0.005 (tested by Student's 2-tailed t test or by one-way analysis of variance)				
Abbreviations: ETS. Environmental tobacco smoke;				

After weighing for sampling strategy in multiple linear analysis, the correlations between DEHP metabolite levels and various body component measures are shown in Table 3. Levels of MEOHP, MEHHP, MECPP, and ΣDEHP were positively associated with weight, BMI, and waist circumference. The correlations between DEHP metabolite levels and parameters of bioelectrical impedance analysis are shown in Table 4. The levels of MEOHP, MEHHP, MECPP, and ΣDEHP were positively correlated with estimated fat mass, estimated percent body fat, ECF, and the ECF/ICF ratio.

Table 3
Linear regression coefficients (S.E.) of body measures with a one-unit increase in ln-DEHP metabolite concentrations in adults, with results weighted for sampling strategy

Body measures		MEHP (µg/g)	P	MEOHP (µg/g)	P	MEHHP (µg/g)	P	MECPP (µg/g)	P	Σ DEHP (µmol/g)
Body weight (kg)										
Model 1	1563/193092305	0.092(0.501)	0.856	2.020(0.760)	0.018	2.047(0.648)	0.007	2.003(0.766)	0.019	2.031(0.749)
Model 2	852/117709513	0.023(0.452)	0.961	1.679(0.572)	0.010	1.704(0.538)	0.006	1.520(0.616)	0.026	1.627(0.593)
Body mass index (kg/m ²)										
Model 1	1563/193092305	0.060(0.157)	0.711	0.679(0.211)	0.006	0.696(0.190)	0.002	0.709(0.227)	0.007	0.705(0.217)
Model 2	852/117709513	0.052(0.145)	0.726	0.598(0.174)	0.004	0.617(0.177)	0.003	0.578(0.200)	0.011	0.602(0.189)
Waist (cm)										
Model 1	1563/193092305	-0.012(0.409)	0.978	1.549(0.534)	0.011	1.532(0.468)	0.005	1.512(0.515)	0.010	1.533(0.521)
Model 2	852/117709513	0.059(0.414)	0.888	1.374(0.423)	0.005	1.342(0.403)	0.005	1.209(0.391)	0.007	1.305(0.411)
Subscapular Skinfold (mm)										
Model 1	1255/1158342664	-0.362(0.210)	0.104	0.082(0.274)	0.770	0.151(0.272)	0.586	0.133(0.278)	0.640	0.073(0.284)
Model 2	687/97486158	-0.423(0.206)	0.058	0.019(0.258)	0.943	0.113(0.258)	0.669	0.038(0.244)	0.877	0.005(0.260)
Triceps Skinfold (mm)										
Model 1	1390/172886004	-0.253(0.180)	0.181	0.263(0.228)	0.267	0.237(0.199)	0.254	0.261(0.256)	0.323	0.237(0.241)
Model 2	763/106411256	-0.198(0.164)	0.245	0.272(0.216)	0.227	0.234(0.200)	0.262	0.205(0.234)	0.395	0.216(0.223)
Model 1 was adjusted for age, gender, race/ethnicity, educational level, household income, smoking status, and metabolic equivalent intensity level for activity.										
Model 2 was adjusted for Model 1 plus caffeine intake, total energy intake, total protein intake, total sugar intake, total carbohydrate intake, and total saturated fatty acid intake.										
Abbreviations: DEHP, di-(2-ethylhexyl) phthalate; MEHP, mono(2-ethylhexyl) phthalate; MEHHP, mono(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono(2-ethyl-oxohexyl) phthalate; MECPP, mono(2-ethyl-5-carboxypentyl) phthalate.										
Σ DEHP was the sum of (MEHP/278) + (MEHHP/294) + (MEOHP/292) + (MECPP/308) and corrected for urine creatinine										

Table 4

Linear regression coefficients (S.E.) of bioelectrical impedance analysis parameters with a one-unit increase in ln-DEHP metabolite concentrations in adults, results weighted for the sampling strategy

Bioelectrical Impedance Analysis		MEHP ($\mu\text{g/g}$)	<i>P</i>	MEOHP ($\mu\text{g/g}$)	<i>P</i>	MEHHP ($\mu\text{g/g}$)	<i>P</i>	MECPP ($\mu\text{g/g}$)	<i>P</i>	Σ DEHP ($\mu\text{mol/g}$)	<i>F</i>
Lean mass (kg)											
Model 1	674/96499431	-0.012(0.320)	0.970	0.654(0.444)	0.162	0.692(0.382)	0.090	0.562(0.481)	0.262	0.635(0.444)	0
Model 2	415/61088209	-0.020(0.296)	0.948	0.608(0.384)	0.134	0.640(0.364)	0.099	0.497(0.416)	0.251	0.579(0.393)	0
Fat mass (kg)											
Model 1	674/96499431	0.806(0.610)	0.206	1.646(0.675)	0.028	1.579(0.617)	0.022	1.639(0.697)	0.033	1.666(0.695)	0
Model 2	415/61088209	1.000(0.546)	0.087	1.716(0.602)	0.012	1.560(0.580)	0.017	1.547(0.639)	0.029	1.651(0.636)	0
Percent body fat (%)											
Model 1	674/96499431	0.419(0.377)	0.285	0.800(0.383)	0.034	0.718(0.368)	0.040	0.808(0.374)	0.047	0.794(0.391)	0
Model 2	415/61088209	0.632(0.352)	0.093	0.951(0.337)	0.013	0.789(0.336)	0.033	0.865(0.348)	0.025	0.894(0.354)	0
Cell membrane capacitance (nF)											
Model 1	674/96499431	-0.024(0.028)	0.416	-0.008(0.022)	0.716	-0.001(0.018)	0.952	-0.014(0.021)	0.525	-0.009(0.020)	0
Model 2	415/61088209	-0.022(0.029)	0.469	-0.002(0.018)	0.925	0.004(0.018)	0.824	-0.009(0.020)	0.653	-0.004(0.020)	0
ECF (L)											
Model 1	674/96499431	0.134(0.101)	0.203	0.321(0.149)	0.049	0.308(0.133)	0.035	0.316(0.167)	0.078	0.327(0.156)	0
Model 2	415/61088209	0.147(0.085)	0.105	0.289(0.126)	0.037	0.271(0.119)	0.038	0.279(0.143)	0.069	0.292(0.134)	0
ICF (L)											
Model 1	674/96499431	-0.106(0.151)	0.493	0.196(0.191)	0.321	0.230(0.162)	0.175	0.139(0.203)	0.505	0.179(0.186)	0
Model 2	415/61088209	-0.120(0.147)	0.430	0.189(0.168)	0.278	0.224(0.160)	0.184	0.123(0.178)	0.498	0.168(0.169)	0
ECF/ICF ratio											
Model 1	471/68616209	0.008(0.003)	0.010	0.008(0.002)	0.004	0.006(0.002)	0.021	0.009(0.003)	0.005	0.008(0.003)	0
Model 2	415/61088209	0.009(0.003)	0.003	0.007(0.002)	0.004	0.005(0.002)	0.041	0.009(0.002)	0.002	0.008(0.002)	0
Model 1 was adjusted for age, gender, race/ethnicity, educational level, household income, smoking status, and metabolic equivalent intensity level for activity.											
Model 2 was adjusted for Model 1 plus caffeine intake, total energy intake, total protein intake, total sugar intake, total carbohydrate intake, and total saturated fatty acid intake.											
Abbreviations: DEHP, di-(2-ethylhexyl) phthalate; MEHP, mono(2-ethylhexyl) phthalate; MEHHP, mono(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono(2-ethyl-oxohexyl) phthalate; MECPP, mono(2-ethyl-5-carboxypentyl) phthalate; ECF, extracellular fluid; ICF, intracellular fluid.											
Σ DEHP was the sum of (MEHP/278) + (MEHHP/294) + (MEOHP/292) + (MECPP/308) and corrected for urine creatinine											

Linear regression coefficients between Σ DEHP, BMI, percent fat mass, and ECF/ICF ratio in different subpopulations are demonstrated in Table 5. The correlations between Σ DEHP levels and BMI were more evident in subjects with older age (≥ 40 years old) and non-active smokers. The relationship between Σ DEHP and estimated percent body fat and the ECF/ICF ratio was more evident in subjects with younger age (20–39 years old), women, and non-Hispanic white ethnicity. In addition, the associations between Σ DEHP and the ECF/ICF ratio were also evident in subjects who were not active smokers.

Table 5
Linear regression coefficients (SE) between ln-ΣDEHP and body composition parameters in different subpopulations of sample subjects with results weighted for sampling strategy

	BMI (kg/m ²)		Percent body fat (%)		ECF/ICF ratio	
	βcoeff (S.E.)	P value	βcoeff (S.E.)	P value	βcoeff (S.E.)	P value
Age, y						
18–39	0.42 (0.37)	0.267	1.06 (0.38)	0.014	0.006 (0.003)	0.044
≥ 40	0.84 (0.31)	0.016	-0.03 (0.57)	0.960	0.010 (0.008)	0.228
Gender						
Men	0.48 (0.39)	0.246	-0.19 (0.52)	0.722	0.002 (0.006)	0.711
Women	0.77 (0.40)	0.073	1.78 (0.45)	0.001	0.011 (0.004)	0.011
Race						
Non-Hispanic White	0.39 (0.18)	0.048	0.98 (0.36)	0.016	0.012 (0.003)	0.001
Others	1.38 (0.46)	0.009	0.63 (0.72)	0.398	-0.001 (0.003)	0.658
Smoking						
Not active smokers	0.50 (0.20)	0.024	0.65 (0.36)	0.089	0.009 (0.002)	0.002
Active smokers	0.83 (0.48)	0.103	0.79 (0.48)	0.118	0.007 (0.006)	0.284
Adjusted for Model 2						
Abbreviations: BMI, body mass index; DEHP, di-(2-ethylhexyl) phthalate; ECF, extracellular fluid; ICF, intracellular fluid.						

Discussion

In the current study, we reported that the levels of DEHP metabolites were positively correlated with parameters of body measures (weight, BMI, and waist circumference) and parameters of BIA (fat mass, estimated percent body fat, ECF, and ECF/ICF ratio). Although the relationship between DEHP exposure and obesity parameters has been extensively studied, this is the first report identifying a positive association between urine DEHP metabolites and ECF and the ECF/ICF ratio in a nationally representative survey of U.S. adults. The representativeness of the study population is the main advantage of this study, and we were able to control many covariates in the comprehensive NHANES database.

Recently, it has been discovered that the effects of environmental toxins, especially those defined as EDCs, can promote obesity and are called "obesogens"^{27,41}. In animal studies, female C3H/N mice exposed to DEHP doses similar to environmental exposures showed increased food intake, body weight, and visceral fat deposits⁴². In male C3H/He mice, chronic exposure to DEHP may induce obesity through changes in energy homeostasis. The synergistic effect of hypothyroidism and hypothalamic leptin resistance is a possible mechanism⁴³. Several recent epidemiological studies have surveyed the association between DEHP exposure and obesity in adults. All the previous studies used BMI/waist/weight gain as markers of obesity. In cross-sectional studies, one study observed that higher MEHP levels were associated with increased obesity prevalence in NHANES 1999–2004²⁸. Another study using data from the 2007–2010 NHANES reported that higher levels of MECPP, MEHHP, and ΣDEHP were associated with an increased prevalence of obesity²⁷. However, other studies found that MEHP levels have inverse associations with obesity in both 1999–2002 NHANES data³¹ and the Nurses' Health Study (NHS) and NHS2 cohorts³⁰. By using a physiologically based pharmacokinetic model, a study reported that the relationship between BMI and DEHP may be explained by higher energy intake and consequent higher DEHP exposure⁴⁴. In prospective analyses, MEOHP levels had positive trends with weight gain between baseline and year 3. However, no statistically significant association was observed after 6 years²⁹. In the current study, we found that higher levels of DEHP metabolites were correlated with higher body measure parameters (weight, BMI, and waist circumference). Differences between studies may be due to a variety of factors, such as race, measurement method, lifestyle, and food.

BMI and waist circumference are generally used as screening tools for being overweight or obese with high specificity²¹. However, these two parameters are less sensitive in identifying adiposity because they cannot distinguish half of people with high body fat⁴⁵. Some experts suggest the value of assessing body-fat percentage, which is more direct for measuring adiposity⁴⁵. In recent years, it has been proven that BIA is a more accurate tool for evaluating body composition and fluid status⁴⁶. Previous studies on DEHP exposure and fat mass were limited to children. Some studies reported that there was no correlation between DEHP exposure and adiposity^{32,34,35}. Another report showed that the associations of DEHP exposure with body fat depended on the timing of exposure³³. In adults, there were few studies studying the association between DEHP exposure and body fat percentage. One study found no correlation between urine MEHP levels and adiposity measures in elderly women³⁷. Another study enrolled participants from NHANES 1999–2006, and the authors reported that there was no association between MEHP and body fat percentage but a negative correlation with lean mass among women³⁶. The difference between our study and the above two studies is that we used many metabolites of DEHP as biological indicators instead of MEHP alone. In this study, we found that the levels of MEOHP, MEHHP, MECPP, and ΣDEHP were positively correlated with estimated fat mass and estimated percent body fat. The results provided evidence that DEHP exposure might increase fat mass/body fat percentage in adults.

The fluid volume in humans depends on age, sex, and body size and is also associated with human health. Extracellular fluid (ECF) is controlled by sodium balance and total body sodium content. Osmolality of the ECF is regulated by water intake and vasopressin secretion, while the ECF volume is maintained by RAAS and some natriuretic factors, including atrial/brain natriuretic peptide¹⁰. In addition, growth hormone and sex hormones have been found to have a role in ECF volume^{24,47}. Environmental chemicals that have the capacity to inhibit 11 β -HSD-2 would be predicted to elevate blood pressure and expand ECF¹⁷. In mice, DEHP exposure has been reported to elevate blood pressure through activation of the RAAS¹⁹. In premature infants, higher levels of postnatal DEHP exposure are correlated with increased blood pressure and hypertension. Statistical analysis showed that this relationship was mediated by the cortisol-to-cortisone ratio, suggesting that the mechanism may be because DEHP inhibits the activity of 11 β -HSD-2 and then activates the mineralocorticoid receptor. In this study, increased expression of ENaC and phosphorylated Na⁺-Cl⁻ cotransporters were also found in hypertensive infants²⁰. Moreover, adipocytes produce 30% of the total blood angiotensinogen⁴⁸ and are also an important source of extra-adrenal aldosterone²². It is possible that DEHP induces activation of RAAS and then contributes to sodium retention and ECF expansion¹⁸. In addition, the mono- and dicarboxylic acid metabolites of DEHP have affinity with the receptors of peroxisome proliferator-activated receptor (PPAR) α and PPAR γ *in vitro* studies²³. Activation of PPAR γ results in enhanced sodium and water reabsorption by upregulation of sodium-hydrogen exchanger 3, the Na-K-2Cl cotransporter, water channels aquaporin-2, and ENaC²⁵. Another possible mechanism is that DEHP has been reported to have estrogenic activity both *in vitro* and *in vivo*⁴⁹. The high estrogen status will then increase ENaC activity via protein kinase C δ signaling in renal cortical collecting duct cells and expand the ECF volume²⁴.

In the current study, we provide the first evidence that the levels of DEHP metabolites are positively correlated with ECF and the ECF/ICF ratio. Increased ECF may cause stress on the cardiovascular system¹², which may be one of the possible mechanisms by which DEHP causes cardiovascular disease. However, this hypothesis still needs further study.

In the subgroup analysis, the correlation between Σ DEHP and the ECF/ICF ratio was more evident in women. Women are exposed to a higher concentration of phthalates than men because of the personal care products they use⁵⁰. Furthermore, a report showed that there were sex differences in the regulation of RAAS. The adrenal response to exogenous angiotensin II was significantly higher in women. It is possible that the effect of DEHP-induced RAAS may be more evident in women than in men⁵¹.

We also found that the association between Σ DEHP and the ECF/ICF ratio was more pronounced among subjects who were not current smokers. Studies show that body composition may be altered by smoking habits^{52,53}. A possible explanation is that DEHP has a much weaker effect on body fluids than tobacco smoke. When considering the impact of DEHP on active smokers, the trend is too small to be statistically significant.

Our research has several limitations. First, causal inference is not suitable for cross-sectional research. Second, when DEHP is exposed, other undetected chemicals may be exposed at the same time, and the correlation found in the research is not caused by DEHP itself. Third, our study population was mainly composed of adults, so we cannot infer that this association also exists in children.

Conclusions

Although previous reports have explored the association between DEHP exposure and obesity parameters, including BMI, waist circumference, and fat percentage in adults, we present the first report identifying a positive association of urine DEHP metabolites with body fluid status in a nationally representative survey of U.S. adults. Since DEHP exposure has become a worldwide concern, further research is necessary to determine the long-term mechanism and effects of low-dose DEHP exposure on human health.

Declarations

Acknowledgments

We would like to thank the many individuals who contributed to the National Health and Nutrition Examination Survey data, including all of the anonymous participants in the present study. We are particularly grateful to those who carried out the laboratory assays for DEHP at the Division of Environmental Health Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention.

Specific author contributions: Wei-Jie Wang and Chia-Sung Wang developed the theoretical concept and manuscript drafting. Chi-Kang Wang helped to perform the analytic calculations. An-Ming Yang helped to record and analyze covariates and critical discussion. Chien-Yu Lin contributed to developing the theoretical concept, recording and analyzing covariates, critical discussion and the final version of the manuscript.

Disclosure statement:

No competing financial interest was declared.

The authors have nothing to disclose.

References

1. Liao, K. W. *et al.* Increased risk of phthalates exposure for recurrent pregnancy loss in reproductive-aged women. *Environmental pollution (Barking, Essex: 1987)* **241**, 969–977, doi:10.1016/j.envpol.2018.06.022 (2018).
2. Wang, W., Leung, A. O. W., Chu, L. H. & Wong, M. H. Phthalates contamination in China: Status, trends and human exposure-with an emphasis on oral intake. *Environmental pollution (Barking, Essex: 1987)* **238**, 771–782, doi:10.1016/j.envpol.2018.02.088 (2018).

3. Meeker, J. D. & Ferguson, K. K. Urinary phthalate metabolites are associated with decreased serum testosterone in men, women, and children from NHANES 2011–2012. *The Journal of clinical endocrinology and metabolism* **99**, 4346–4352, doi:10.1210/jc.2014-2555 (2014).
4. Hoppin, J. A., Brock, J. W., Davis, B. J. & Baird, D. D. Reproducibility of urinary phthalate metabolites in first morning urine samples. *Environmental health perspectives* **110**, 515–518 (2002).
5. Wang, I. J., Lin, C. C., Lin, Y. J., Hsieh, W. S. & Chen, P. C. Early life phthalate exposure and atopic disorders in children: a prospective birth cohort study. *Environment international* **62**, 48–54, doi:10.1016/j.envint.2013.09.002 (2014).
6. Schaedlich, K. *et al.* DEHP deregulates adipokine levels and impairs fatty acid storage in human SGBS-adipocytes. *Scientific reports* **8**, 3447, doi:10.1038/s41598-018-21800-4 (2018).
7. James-Todd, T. *et al.* Urinary phthalate metabolite concentrations and diabetes among women in the National Health and Nutrition Examination Survey (NHANES) 2001–2008. *Environmental health perspectives* **120**, 1307–1313, doi:10.1289/ehp.1104717 (2012).
8. Trasande, L. *et al.* Urinary phthalates are associated with higher blood pressure in childhood. *The Journal of pediatrics* **163**, 747–753 e741, doi:10.1016/j.jpeds.2013.03.072 (2013).
9. Edelman, I. S. & Leibman, J. Anatomy of body water and electrolytes. *The American journal of medicine* **27**, 256–277, doi:10.1016/0002-9343(59)90346-8 (1959).
10. Roumelioti, M. E. *et al.* Fluid balance concepts in medicine: Principles and practice. *World journal of nephrology* **7**, 1–28, doi:10.5527/wjn.v7.i1.1 (2018).
11. Seo, H. S. *et al.* Extracellular fluid adjusted for body size is contracted in hypertension. *Hypertension research: official journal of the Japanese Society of Hypertension* **36**, 916–921, doi:10.1038/hr.2013.68 (2013).
12. Park, S. *et al.* Extracellular Fluid Excess Is Significantly Associated With Coronary Artery Calcification in Patients With Chronic Kidney Disease. *Journal of the American Heart Association* **7**, doi:10.1161/jaha.118.008935 (2018).
13. Lee, J. Y., Ryu, H. S., Yoon, S. S., Kim, E. H. & Yoon, S. W. Extracellular-to-Intracellular Fluid Volume Ratio as a Prognostic Factor for Survival in Patients With Metastatic Cancer. *Integrative cancer therapies* **18**, 1534735419847285, doi:10.1177/1534735419847285 (2019).
14. Chen, W., Guo, L. J. & Wang, T. Extracellular water/intracellular water is a strong predictor of patient survival in incident peritoneal dialysis patients. *Blood purification* **25**, 260–266, doi:10.1159/000101699 (2007).
15. Kim, E. J. *et al.* Extracellular Fluid/Intracellular Fluid Volume Ratio as a Novel Risk Indicator for All-Cause Mortality and Cardiovascular Disease in Hemodialysis Patients. *PloS one* **12**, e0170272, doi:10.1371/journal.pone.0170272 (2017).
16. Lin, Y.-P. *et al.* The extracellular fluid–to–intracellular fluid volume ratio is associated with large-artery structure and function in hemodialysis patients. *American Journal of Kidney Diseases* **42**, 990–999, doi:https://doi.org/10.1016/j.ajkd.2003.07.002 (2003).
17. Kirkley, A. G. & Sargis, R. M. Environmental endocrine disruption of energy metabolism and cardiovascular risk. *Current diabetes reports* **14**, 494, doi:10.1007/s11892-014-0494-0 (2014).
18. Harrison-Bernard, L. M. The renal renin-angiotensin system. *Advances in physiology education* **33**, 270–274, doi:10.1152/advan.00049.2009 (2009).
19. Xie, X. *et al.* Comparing the effects of diethylhexyl phthalate and dibutyl phthalate exposure on hypertension in mice. *Ecotoxicology and environmental safety* **174**, 75–82, doi:10.1016/j.ecoenv.2019.02.067 (2019).
20. Jenkins, R. *et al.* Phthalate-associated hypertension in premature infants: a prospective mechanistic cohort study. *Pediatric nephrology (Berlin, Germany)* **34**, 1413–1424, doi:10.1007/s00467-019-04244-4 (2019).
21. Ribeiro, C. *et al.* Association between the exposure to phthalates and adiposity: A meta-analysis in children and adults. *Environmental research* **179**, 108780, doi:10.1016/j.envres.2019.108780 (2019).
22. Briones, A. M. *et al.* Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. *Hypertension (Dallas, Tex.: 1979)* **59**, 1069–1078, doi:10.1161/hypertensionaha.111.190223 (2012).
23. Ito, Y., Kamijima, M. & Nakajima, T. Di(2-ethylhexyl) phthalate-induced toxicity and peroxisome proliferator-activated receptor alpha: a review. *Environmental health and preventive medicine* **24**, 47, doi:10.1186/s12199-019-0802-z (2019).
24. Yusef, Y. R., Thomas, W. & Harvey, B. J. Estrogen increases ENaC activity via PKC δ signaling in renal cortical collecting duct cells. *Physiological reports* **2**, doi:10.14814/phy2.12020 (2014).
25. Fu, Y. *et al.* PPAR γ agonist-induced fluid retention depends on α ENaC expression in connecting tubules. *Nephron* **129**, 68–74, doi:10.1159/000370254 (2015).
26. Khalil, S. F., Mohktar, M. S. & Ibrahim, F. The Theory and Fundamentals of Bioimpedance Analysis in Clinical Status Monitoring and Diagnosis of Diseases. *Sensors* **14**, 10895–10928 (2014).
27. Buser, M. C., Murray, H. E. & Scinicariello, F. Age and sex differences in childhood and adulthood obesity association with phthalates: analyses of NHANES 2007–2010. *International journal of hygiene and environmental health* **217**, 687–694, doi:10.1016/j.ijheh.2014.02.005 (2014).
28. Yaghjian, L., Sites, S., Ruan, Y. & Chang, S. H. Associations of urinary phthalates with body mass index, waist circumference and serum lipids among females: National Health and Nutrition Examination Survey 1999–2004. *International journal of obesity (2005)* **39**, 994–1000, doi:10.1038/ijo.2015.8 (2015).
29. Díaz Santana, M. V. *et al.* Urinary concentrations of phthalate biomarkers and weight change among postmenopausal women: a prospective cohort study. *Environmental health: a global access science source* **18**, 20, doi:10.1186/s12940-019-0458-6 (2019).
30. Song, Y. *et al.* Urinary concentrations of bisphenol A and phthalate metabolites and weight change: a prospective investigation in US women. *International journal of obesity (2005)* **38**, 1532–1537, doi:10.1038/ijo.2014.63 (2014).

31. Hatch, E. E. *et al.* Association of urinary phthalate metabolite concentrations with body mass index and waist circumference: a cross-sectional study of NHANES data, 1999–2002. *Environmental health: a global access science source* **7**, 27, doi:10.1186/1476-069x-7-27 (2008).
32. Buckley, J. P. *et al.* Prenatal Phthalate Exposures and Childhood Fat Mass in a New York City Cohort. *Environmental health perspectives* **124**, 507–513, doi:10.1289/ehp.1509788 (2016).
33. Shoaff, J. *et al.* Early-Life Phthalate Exposure and Adiposity at 8 Years of Age. *Environmental health perspectives* **125**, 097008, doi:10.1289/ehp1022 (2017).
34. Maresca, M. M. *et al.* Prenatal Exposure to Phthalates and Childhood Body Size in an Urban Cohort. *Environmental health perspectives* **124**, 514–520, doi:10.1289/ehp.1408750 (2016).
35. Chang, C. H. *et al.* The sex-specific association of phthalate exposure with DNA methylation and characteristics of body fat in children. *The Science of the total environment* **737**, 139833, doi:10.1016/j.scitotenv.2020.139833 (2020).
36. Corbasson, I., Hankinson, S. E., Stanek, E. J., 3rd & Reeves, K. W. Urinary bisphenol-A, phthalate metabolites and body composition in US adults, NHANES 1999–2006. *International journal of environmental health research* **26**, 606–617, doi:10.1080/09603123.2016.1233524 (2016).
37. Lind, P. M. *et al.* Serum concentrations of phthalate metabolites are related to abdominal fat distribution two years later in elderly women. *Environmental health: a global access science source* **11**, 21, doi:10.1186/1476-069x-11-21 (2012).
38. *NHANES 2003–2004*, <http://wwwn.cdc.gov/Nchs/Nhanes/Search/nhanes03_04.aspx> (2008).
39. Braun, J. M. *et al.* Variability of urinary phthalate metabolite and bisphenol A concentrations before and during pregnancy. *Environmental health perspectives* **120**, 739–745, doi:10.1289/ehp.1104139 (2012).
40. *ANALYTIC AND REPORTING GUIDELINES: The National Health and Nutrition Examination Survey (NHANES)*, <http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/nhanes_analytic_guidelines_dec_2005.pdf> (2005).
41. Grün, F. & Blumberg, B. Environmental obesogens: organotins and endocrine disruption via nuclear receptor signaling. *Endocrinology* **147**, S50–55, doi:10.1210/en.2005-1129 (2006).
42. Schmidt, J. S., Schaedlich, K., Fiandanese, N., Pocar, P. & Fischer, B. Effects of di(2-ethylhexyl) phthalate (DEHP) on female fertility and adipogenesis in C3H/N mice. *Environmental health perspectives* **120**, 1123–1129, doi:10.1289/ehp.1104016 (2012).
43. Lv, Z. *et al.* DEHP induces obesity and hypothyroidism through both central and peripheral pathways in C3H/He mice. *Obesity (Silver Spring, Md.)* **24**, 368–378, doi:10.1002/oby.21359 (2016).
44. Campbell, J. L., Jr. *et al.* Excretion of Di-2-ethylhexyl phthalate (DEHP) metabolites in urine is related to body mass index because of higher energy intake in the overweight and obese. *Environment international* **113**, 91–99, doi:10.1016/j.envint.2018.01.023 (2018).
45. Okorodudu, D. O. *et al.* Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. *International journal of obesity (2005)* **34**, 791–799, doi:10.1038/ijo.2010.5 (2010).
46. de-Mateo-Silleras, B. *et al.* Bioelectrical impedance vector analysis in obese and overweight children. *PloS one* **14**, e0211148, doi:10.1371/journal.pone.0211148 (2019).
47. Johannsson, G., Gibney, J., Wolthers, T., Leung, K. C. & Ho, K. K. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. *The Journal of clinical endocrinology and metabolism* **90**, 3989–3994, doi:10.1210/jc.2005-0553 (2005).
48. Padilla, J., Vieira-Potter, V. J., Jia, G. & Sowers, J. R. Role of perivascular adipose tissue on vascular reactive oxygen species in type 2 diabetes: a give-and-take relationship. *Diabetes* **64**, 1904–1906, doi:10.2337/db15-0096 (2015).
49. Chen, X. *et al.* Toxicity and estrogenic endocrine disrupting activity of phthalates and their mixtures. *International journal of environmental research and public health* **11**, 3156–3168, doi:10.3390/ijerph110303156 (2014).
50. Parlett, L. E., Calafat, A. M. & Swan, S. H. Women's exposure to phthalates in relation to use of personal care products. *Journal of exposure science & environmental epidemiology* **23**, 197–206, doi:10.1038/jes.2012.105 (2013).
51. Toering, T. J. *et al.* Sex differences in renin-angiotensin-aldosterone system affect extracellular volume in healthy subjects. *American journal of physiology. Renal physiology* **314**, F873-f878, doi:10.1152/ajprenal.00109.2017 (2018).
52. Kleppinger, A., Litt, M. D., Kenny, A. M. & Oncken, C. A. Effects of smoking cessation on body composition in postmenopausal women. *Journal of women's health (2002)* **19**, 1651–1657, doi:10.1089/jwh.2009.1853 (2010).
53. Efendi, V., Özalevli, S., Naz, İ. & Kılınc, O. The effects of smoking on body composition, pulmonary function, physical activity and health-related quality of life among healthy women. *Tuberkuloz ve toraks* **66**, 101–108, doi:10.5578/tt.50724 (2018).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementalsection.docx](#)